Head-to-head · WeighScore
Nouri vs Tablet Health
The verdict
Nouri takes it — 54.8/100 to 47.6/100.
Nouri grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nouri is a DTC telehealth platform offering compounded semaglutide and tirzepatide bundled with nutrition and movement planning plus clinician messaging — lifestyle support included rather than upsold.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Nouri | Tablet Health |
|---|---|---|
| WeighScore | 54.8/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #455 | #495 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #455 · C
Strengths
- Named clinical MSO partner (Wasef Health, PC; Michael Wasef, MD) with public contact email
- Named 503A compounding pharmacy partner (Jungle Jim's Pharmacy, Fairfield OH) with full address
- Available in all 50 states per the FAQ
- Flat per-dose pricing within each tier — no dose-escalation surcharge
- Nutrition and movement coaching included in the medication price
Where it loses points
- Compounded medications only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
- Operating entity name not disclosed in the Terms of Service
- Terms 'where we operate' language is slightly weaker than the FAQ's all-50-states claim
- Video visit required in some states, but those states aren't listed
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.